The heart of drug discovery and development: rational target selection

Pharmacology. 2006;77(2):85-92. doi: 10.1159/000093166. Epub 2006 May 5.

Abstract

Critical to the discovery and development of drugs and vaccines is the rational selection of biochemical, immunologic or molecular targets. To understand the rationale for target selection, we review strengths and weaknesses of the four main approaches: whole animal disease models; molecular targeting; epidemiology/observation studies, and genomics. After classifying diseases into those with a relatively stable pathophysiology (e.g., hypertension and gout) versus those with an unstable pathophysiology (e.g., AIDS and influenza) to aid in understanding target selection, we provide examples of successful and unsuccessful selection of drug and vaccine targets, focusing on the molecular and epidemiological/observational approaches. We discuss the reasons that molecular targeting has led to successful control of many diseases, whereas the epidemiological/observational approach has had a checkered history. We also assess the potential power of the genomic approach, specifically the curative versus controlling/preventive strategies. With combined genetic and molecular approaches and judicious use of whole animal models and properly performed epidemiology/observation studies to select the appropriate targets, the future for controlling, preventing and even curing many diseases is very bright indeed.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Bone Density Conservation Agents / therapeutic use
  • Cholecystokinin / antagonists & inhibitors
  • Denosumab
  • Diphosphonates / therapeutic use
  • Drug Design*
  • Drug Evaluation, Preclinical
  • Epidemiologic Studies
  • Estrogen Replacement Therapy
  • Genomics
  • Humans
  • Osteoporosis / drug therapy
  • RANK Ligand

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bone Density Conservation Agents
  • Diphosphonates
  • RANK Ligand
  • Denosumab
  • Cholecystokinin